Status: Recruiting
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.
Participants needed: 168
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Kathy MillerUpdated: Sep 3, 2026Locations: 7
Eligibility criteria
≥ 18 years old at the time of informed consent [+30]
Prior treatment with or known contraindication to treatment with tocilizumab bio... [+8]